These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26957644)

  • 1. Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics.
    Davies KM; Mercer JF; Chen N; Double KL
    Clin Sci (Lond); 2016 Apr; 130(8):565-74. PubMed ID: 26957644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases.
    Dusek P; Roos PM; Litwin T; Schneider SA; Flaten TP; Aaseth J
    J Trace Elem Med Biol; 2015; 31():193-203. PubMed ID: 24954801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transition metals copper and iron in neurodegenerative diseases.
    Rivera-Mancía S; Pérez-Neri I; Ríos C; Tristán-López L; Rivera-Espinosa L; Montes S
    Chem Biol Interact; 2010 Jul; 186(2):184-99. PubMed ID: 20399203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic approaches for Parkinson's disease by targeting brain cholesterol homeostasis.
    Pingale TD; Gupta GL
    J Pharm Pharmacol; 2021 Jun; 73(7):862-873. PubMed ID: 33822122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics.
    Belaidi AA; Bush AI
    J Neurochem; 2016 Oct; 139 Suppl 1():179-197. PubMed ID: 26545340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper Ions and Parkinson's Disease: Why Is Homeostasis So Relevant?
    Bisaglia M; Bubacco L
    Biomolecules; 2020 Jan; 10(2):. PubMed ID: 32013126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis).
    Gaggelli E; Kozlowski H; Valensin D; Valensin G
    Chem Rev; 2006 Jun; 106(6):1995-2044. PubMed ID: 16771441
    [No Abstract]   [Full Text] [Related]  

  • 8. Alpha-synuclein and iron: two keys unlocking Parkinson's disease.
    Lingor P; Carboni E; Koch JC
    J Neural Transm (Vienna); 2017 Aug; 124(8):973-981. PubMed ID: 28168622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper imbalance and oxidative stress in neurodegeneration.
    Rossi L; Arciello M; Capo C; Rotilio G
    Ital J Biochem; 2006; 55(3-4):212-21. PubMed ID: 17274527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR: a therapeutic target in Parkinson's disease.
    Chaturvedi RK; Beal MF
    J Neurochem; 2008 Jul; 106(2):506-18. PubMed ID: 18384649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance.
    Rossi L; Lombardo MF; Ciriolo MR; Rotilio G
    Neurochem Res; 2004 Mar; 29(3):493-504. PubMed ID: 15038597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders.
    Giampietro R; Spinelli F; Contino M; Colabufo NA
    Mol Pharm; 2018 Mar; 15(3):808-820. PubMed ID: 29323501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
    Ahlskog JE; Uitti RJ; Low PA; Tyce GM; Nickander KK; Petersen RC; Kokmen E
    Mov Disord; 1995 Sep; 10(5):566-73. PubMed ID: 8552107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper-dependent oxidative stress and neurodegeneration.
    Rotilio G; Carrì MT; Rossi L; Ciriolo MR
    IUBMB Life; 2000; 50(4-5):309-14. PubMed ID: 11327325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.
    Schapira AH; Olanow CW; Greenamyre JT; Bezard E
    Lancet; 2014 Aug; 384(9942):545-55. PubMed ID: 24954676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redox active metals in neurodegenerative diseases.
    Acevedo K; Masaldan S; Opazo CM; Bush AI
    J Biol Inorg Chem; 2019 Dec; 24(8):1141-1157. PubMed ID: 31650248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuronal response in Alzheimer's and Parkinson's disease: the effect of toxic proteins on intracellular pathways.
    Majd S; Power JH; Grantham HJ
    BMC Neurosci; 2015 Oct; 16():69. PubMed ID: 26499115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof.
    Verwilst P; Sunwoo K; Kim JS
    Chem Commun (Camb); 2015 Apr; 51(26):5556-71. PubMed ID: 25647245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.